Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes

Haematologica

Volumn 91, Issue 5, 2006, Pages 667-670

  Broliden, Per Anders ^a   Dahl, Inger Marie ^b   Hast, Robert ^a   Johansson, Bertil ^c   Juvonen, Eeva ^d   Kjeldsen, Lars ^e   Porwit MacDonald, Anna ^a   Sjoo, Malvin ^f   Tangen, Jon Magnus ^g   Uggla, Bertil ^h   Oberg, Gunnar ⁱ   Hellström Lindberg, Eva ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e Rigshospitalet   (Denmark)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^h ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

ⁱ UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ATG; Cyclosporine A; MDS; Treatment

Indexed keywords

CYCLOSPORIN A; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTENSION; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; REFRACTORY ANEMIA; REMISSION; RISK FACTOR; SIDEROBLASTIC ANEMIA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33744492061     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Aul C, Bowen D, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998;83:71-86.
2. Hellström-Lindberg E, Kanter-Lewensohn L, Öst Å. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res 1997;21:415-25.
3. Westwood NB, Mufti GJ. Apoptosis in the myelodysplastic syndromes. Curr Hematol Rep 2003;2:186-92.
4. Tehranchi R, Fadeel B, Forsblom AM, Christensson B, Samuelsson J, Zhivotovsky B, et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 2003;101:1080-6.
5. Hellström-Lindberg E, Willman C, Barrett AJ, Saunthararajah Y. Achievements in understanding and treatment of myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 2000;110-32.
6. Kondo Y, Molldrem JJ. Immune-induced cytopenia: bone marrow failure syndrome. Curr Hematol Rep 2004;3:178-83.
7. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Anti-thymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997;99:699-705.
8. Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC, Bowen DT, Marsh JC. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003;120:679-84.
9. Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004;18:460-5.
10. Yazji S, Giles FJ, Tsimberidou AM, Estey EH, Kantarjian HM, O'Brien SA, et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003;17:2101-6.
11. Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A. Anti-thymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003;101:2156-8.
12. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002;137:156-63.
13. Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewski JP, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002;100:1570-4.
14. Jonasova A, Neuwirtova R, Cermak J, Vozobulova V, Mocikova K, Siskova M, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998;100:304-9.
15. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. The German Aplastic Anemia Study Group. Blood 2003;101:1236-42.
16. Bennett JM, Catovsky D, Daniel M, Flandrin G, Galton D, Gralnick H, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
17. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
18. Johansson B, Mertens F, Mitelman F. Primary vs. secondary neoplasia-associated chromosomal abnormalities - balanced rearrangements vs. genomic imbalances? Genes Chromosomes Cancer 1996;16:155-63.